The research, led by Sylvain Gourier and Marwan Bouras of Brest University Hospital Centre in France, together with colleagues in Quebec and Nantes, set out to answer a deceptively simple question: when AMPA receptor antagonists are administered after a traumatic brain injury in mammals, do they actually make things better? The team searched three major biomedical databases, MEDLINE, Embase and Web of Science, and screened 410 records to arrive at a final set of eleven studies that met their strict inclusion criteria. Only mammalian in vivo experiments in which an AMPA receptor antagonist was given after the injury and compared against a vehicle control, no treatment, or an alternative intervention were eligible, a design intended to mirror as closely as possible the clinical scenario in which a patient arrives at a hospital after the insult has already occurred.

The biological rationale behind this line of investigation runs deep. When the brain is subjected to mechanical trauma, damaged and dying cells flood the extracellular space with glutamate, the principal excitatory neurotransmitter of the central nervous system. Under normal conditions, glutamate transmission is tightly regulated, but after injury the excess glutamate overstimulates its receptors, provoking a cascade known as excitotoxicity. Calcium floods into neurons through ion channels, mitochondrial function collapses, free radicals accumulate, and cells that survived the initial blow die a slow secondary death over hours to days. Because this secondary injury unfolds on a timescale that leaves a therapeutic window, interrupting it with receptor blockers has long been an attractive strategy. Previous attempts targeting the related NMDA receptor ultimately failed in human trials, but the AMPA receptor, which mediates the fast component of excitatory synaptic transmission and can become calcium-permeable after injury, has re-emerged as a distinct and possibly more tractable target.

To conduct the meta-analysis, two reviewers independently screened the candidate studies, extracted the data and appraised methodological quality and risk of bias using two established instruments: the CAMARADES checklist, developed specifically for pooling animal data from experimental studies, and the SYRCLE tool, which probes sources of bias in laboratory animal research. The primary outcome was neurobehavioural performance, assessed across three distinct domains: neurological deficit, cognition and memory, and motor coordination. Secondary outcomes included the severity of brain lesions, mortality, and inflammatory biomarkers. The team applied random-effects meta-analysis, expressing treatment effects as standardized mean differences, a statistical approach that allows results measured on different behavioural scales in different laboratories to be combined into a single estimate.

The headline result is striking for cognition. Across five studies, AMPA receptor antagonists produced a large improvement in cognition and memory, with a standardized mean difference of 1.53 and a tight 95 percent confidence interval running from 1.06 to 2.01. Perhaps more importantly for the credibility of the finding, the statistical heterogeneity across these studies was almost nonexistent, with an I-squared value of just 3 percent, meaning the effect was remarkably consistent from one experiment to the next. In a field where preclinical results often vary wildly between laboratories, this kind of uniformity is rare and lends considerable weight to the conclusion that AMPA blockade genuinely protects the injured, memory-forming circuits of the hippocampus and surrounding structures.

Neurological deficit scores also favoured the drug-treated animals, with a standardized mean difference of 1.28 across four studies, although the confidence interval here, stretching from 0.05 to 2.50, barely excludes zero and the heterogeneity was high at 78 percent, signalling that study designs, drug choices or injury models differed in ways that materially affected the results. Motor coordination told a different story altogether: pooling two studies yielded a standardized mean difference of minus 1.00 with a confidence interval spanning from minus 2.96 to 0.96 and extreme heterogeneity of 83 percent, which the authors interpret as no reliable benefit for motor function. This dissociation between cognitive and motor outcomes is biologically plausible, since AMPA receptor signalling is central to synaptic plasticity in memory circuits, while motor recovery after trauma may depend on mechanisms that pharmacological receptor blockade cannot rescue, or may even require intact AMPA-mediated signalling for compensatory plasticity to occur.

Beyond behaviour, the drugs left visible marks on the injured brain itself. In seven studies measuring lesion severity, AMPA receptor antagonists significantly reduced the extent of tissue damage, with a standardized mean difference of minus 1.39 and moderate heterogeneity of 53 percent. The included experiments spanned several generations of compounds, from early competitive antagonists such as NBQX and the quinoxalinediones ZK200775 and YM872 to the noncompetitive agent talampanel and, more recently, perampanel, the first AMPA antagonist approved for clinical use as an antiepileptic drug. Several of the newer studies also documented consistent reductions in inflammatory biomarkers, aligning with work showing that perampanel dampens oxidative stress, pyroptosis and neuroinflammation through pathways involving molecules such as Sirt3, and protects the neurovascular unit that maintains the blood-brain barrier. Mortality, by contrast, showed no significant effect, a reminder that preventing cellular cascades of damage does not necessarily translate into survival advantages in these models.

The authors are careful to frame their conclusions within the limits of the evidence. Some results, particularly those for neurological deficit and motor coordination, rest on small numbers of studies with substantial statistical heterogeneity and should be interpreted with caution. Publication bias, a chronic problem in animal research in which positive results are more likely to be published than negative ones, may also inflate the apparent effect sizes. The protocol was prospectively registered on the Open Science Framework in April 2025, and the team followed PRISMA reporting guidelines, measures that improve transparency but cannot conjure data that were never collected. The related clinical picture remains sobering: an earlier systematic review by the same senior group found that excitatory amino acid inhibitors have not demonstrated clear benefit in human trials of acute traumatic brain injury, and the field’s history with NMDA antagonists, which failed despite promising animal data, haunts every new preclinical success.

Yet the timing of this analysis is propitious, because the preclinical evidence now intersects with a genuinely new clinical opportunity. Perampanel is already approved and in widespread use for epilepsy, with a growing literature documenting its safety, tolerability, brain penetration and even intravenous formulations suitable for critically ill patients. A phase-two multicentre randomised clinical trial, known as PEACE-TBI, has been designed in Japan to test whether perampanel can alleviate secondary injury after traumatic brain injury in humans. Against that backdrop, the present meta-analysis provides exactly the kind of rigorous synthesis of the animal evidence that trial designers and funders need, confirming biological plausibility for the neurobehavioural and lesion-reducing effects while honestly flagging the outcomes, motor recovery and mortality, where the signal is weak or absent. Whether AMPA receptor antagonists can finally break the decades-long cycle of failed neuroprotection in traumatic brain injury will be decided in patients, but the laboratory evidence assembled here suggests the hypothesis deserves its day in the clinic.

Subject of Research: Efficacy of AMPA receptor antagonists in preclinical animal models of traumatic brain injury

Article Title: AMPA Receptor Antagonists in Preclinical Models of Traumatic Brain Injury: A Systematic Review and Meta-analysis of Animal Studies

Article References: Gourier, S., Morin, C., Gargadennec, T., Turgeon, A. F., Poulain, C., Roquilly, A., Caillard, A., Langeron, O., & Bouras, M. (2026). AMPA Receptor Antagonists in Preclinical Models of Traumatic Brain Injury: A Systematic Review and Meta-analysis of Animal Studies. Neurocritical Care. https://doi.org/10.1007/s12028-026-02640-x

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02640-x

Keywords: traumatic brain injury, AMPA receptor antagonists, excitotoxicity, neuroprotection, perampanel, systematic review, meta-analysis, preclinical models, neurobehavioural outcomes, brain lesion severity, neuroinflammation, glutamate receptors